To confirm that the changes in gene expression observed in neuroblastoma cells treated with STM2457 were due to targeting METTL3, we analyzed CHGA and NTRK1 mRNA levels in control SK-N-BE2 cells and cells engineered to overexpress METTL3. This evidence concerns the gene NTRK1 and neuroblastoma.